ScholarLens Back to search
2013•MD Conference ExpressRequires access

Lower-Dose Etanercept Plus Methotrexate Shows Benefit for Early RA Patients in PRIZE Trial

Lori Hand, Paul Emery

Open publisher page 0 citations

Abstract

In patient-reported outcomes for those with recently diagnosed rheumatoid arthritis, treatment with etanercept 25 mg plus methotrexate (MTX) was superior to MTX plus placebo or placebo alone in maintenance of remission and therapeutic effect. This article discusses a poster of the results of A 3-Phase Study to Evaluate Sustained Remission and Productivity Outcomes in Subjects With Early Rheumatoid Arthritis Initiated on Treatment With Etanercept Plus Methotrexate [PRIZE; EUCTR2008-00263-85-IT; Emery P et al. EULAR 2013 (poster 0543)].

About this research paper

What this paper is about

In patient-reported outcomes for those with recently diagnosed rheumatoid arthritis, treatment with etanercept 25 mg plus methotrexate (MTX) was superior to MTX plus placebo or placebo alone in maintenance of remission and therapeutic effect. This article discusses a poster of the results of A 3-Phase Study to Evaluate Sustained Remission and Productivity Outcomes in Subjects With Early Rheumatoid Arthritis Initiated on Treatment With Etanercept Plus Methotrexate [PRIZE; EUCTR2008-00263-85-IT; Emery P et al. EULAR 2013 (poster 0543)].

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

In patient-reported outcomes for those with recently diagnosed rheumatoid arthritis, treatment with etanercept 25 mg plus methotrexate (MTX) was superior to MTX plus placebo or placebo alone in maintenance of remission and therapeutic effect. This article discusses a poster of the results of A 3-Phase Study to Evaluate Sustained Remission and Productivity Outcomes in Subjects With Early Rheumatoid Arthritis Initiated on Treatment With Etanercept Plus Methotrexate [PRIZE; EUCTR2008-00263-85-IT; Emery P et al. EULAR 2013 (poster 0543)].

Key concepts: Etanercept, Methotrexate, Rheumatoid arthritis, Medicine, Placebo, Internal medicine, Arthritis, Antirheumatic Agents

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Lower-Dose Etanercept Plus Methotrexate Shows Benefit for Early RA Patients in PRIZE Trial — Research Paper | ScholarLens